IRCT20210914052480N2 IRCT 2022-07-07 Bagheiat-allah University of Medical Sciences The efficacy of molnupiravir in patients with COVID-19 Comparing the efficacy of Molnupiravir and placebo on recovery rate in patients with mild COVID-19, a randomized multicenter clinical trial 2022-04-21 anticipated 500 Complete https://irct.ir/trial/60762 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the Block Randomization method will be used using blocks of four in random order. In this method, treatment blocks are moved back and forth randomly, for example, with a block of length 4 and with two treatment groups, there are the following possibilities ABBB, ABAB, ABBA, BABA, BAAB, BBAA By putting these blocks together randomly, a balanced random list of two treatment groups is obtained, Blinding description: In this study, patients participating in the clinical trial and individuals collecting patient data will not be aware of the intervention groups. Mulnopiravir and placebo will be exactly the same, and no one will know the contents until the end of the study. 2-3 COVID-19. Intervention 1: Intervention group: The group receiving oral molnopiravir 200 mg daily for up to five days after the intervention, with diphenhydramine syrup / vitamin C tablet / vitamin D tablet / famotidine 40 mg tablet every 12 hours (in case of fever and pain Muscle naproxen 250 mg daily or twice daily will be added). Intervention 2: Control group: This group will receive placebo exactly similar to molnopiravir for five days, with diphenhydramine syrup, vitamin C tablets, vitamin D tablets, famotidine 40mg tablets every 12 hours, and naproxen 250 in case of fever and muscle aches. They will receive it once or twice a day. Yes - There is a plan to make this available What will be shared: The data can be used by others without any personal information of patients When: after data gathering completion To whom: Only people with relevant permissions to use confidential information Conditions: The data can be used for statistical analysis and re-examination Where to obtain: Morteza Izadi; access through email: morteza_izadi@yahoo.com How to obtain: After calling or sending an email, the data will be sent if the applicant is valid Comments: